AI assistant
Sending…
Altimmune, Inc. — Director's Dealing 2010
May 11, 2010
33207_dirs_2010-05-10_2931af14-214c-46a5-9d4a-ea1c8d705ae3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-05-06
Reporting Person: Karp Jordan P (SVP, General Counsel)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2010-05-06 | Stock Option (right to buy) | $1.38 | A | 50000 | Acquired | 2020-05-06 | Common Stock (50000) | Direct |
Footnotes
F1: On May 6, 2010, the date such options were granted, the closing price of the Issuer's Common Stock on the NYSE Amex was $1.38
per share.
F2: The option vests over a 4 year period with 25% each vesting on the first, second, third and fourth anniversaries of the grant
date.
More from Altimmune, Inc.
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Capital/Financing Update
2026
Apr 22
Declaration of Voting Results & Voting Rights Announcements
2026
Apr 16
Major Shareholding Notification
2026
Mar 26
Annual Report
2026
Mar 17
Proxy Solicitation & Information Statement
2026
Mar 17
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 27
Regulatory Filings
2026
Feb 6